Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 7, 2004, Pages 3319-3325

  Khan, Aliya A ^a   Bilezikian, John P ^b   Kung, Annie W C ^c   Ahmed, Mustafa M ^a   Dubois, Sacha J ^a   Ho, Andrew Y Y ^c   Schussheim, Debra ^b   Rubin, Mishaela R ^b   Shaikh, Atif M ^a   Silverberg, Shonni J ^b   Standish, Timothy I ^a   Syed, Zareen ^a   Syed, Zeba A ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; FEMALE; FEMUR NECK; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; LUMBAR SPINE; MALE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HIP JOINT; HUMANS; HYPERPARATHYROIDISM; LUMBOSACRAL REGION; MALE; MIDDLE AGED; PEPTIDES; PLACEBOS; RADIUS; SPINE;

EID: 3242682209     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030908     Document Type: Article

References (24)

1. Khan A, Bilezikian JP 2000 Primary hyperparathyroidism: pathophysiology and impact on bone. Can Med Assoc J 63:184-187
2. Potts Jr JT, Fradkin JE, Aurbach GD, Bilezikian JP, Raisz LG, eds 1991 Proceedings of the NIH Consensus Development Conference on Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism. J Bone Miner Res 6(Suppl 2):S1-S165.
3. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249-1255
4. Bilezikian JP, Potts Jr JT, Fuleihan GE, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA 2002 Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 17(Suppl 2):N2-N11
5. Khan AA, Hanley DA, O'Brien CJ, Pasieka J, Ste-Marie LG, Rotstein LE, Rosen I, Young JEM, Josse RG, Bilezikian JP 2003 Position paper: Asymptomatic primary hyperparathyroidism - standards and guidelines for diagnosis and management in Canada. Endocr Pract 9:400-405
6. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid JR 1996 Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 125:360-368
7. Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR 2000 Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 160:2161-2166
8. Silverberg SJ, Marriott TB, Bone III HG, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Sanguinetti ES, Bilezikian JP 1997 Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337:1506-1510
9. Peacock M, Bilezikian JP, Turner SA, Guo MD, McCary LC, Koenig KG, Shoback DM, Long term treatment with the calcimimetic AMG 073 in patients with primary hyperparathyroidism (PHPT). Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, p 92 (Abstract R21-2)
10. Shane E, Baquiran DC, Bilezikian JP 1981 Effects of dichloromethylene diphosphate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med 95:23-27
11. Hamdy NA, Gray RD, McCloskey E, Galloway J, Rattenbury JM, Brown CB, Kanis JA 1987 Clodronate in the medical management of hyperparathyroidism. Bone 8(Suppl 1):S69-S77
12. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR 1993 Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 77:1067-1071
13. Hassani S, Braunstein GD, Seibel MJ, Brickman AS, Geola FL, Pekary AE, Hershman JM 2001 Alendronate therapy of primary hyperparathyroidism. Endocrinologist 11:459-464
14. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S 2001 Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 16:113-119
15. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ 2002 Hyperparathyroid-related osteoporosis: a 2-year study. J Clin Enocrinol Metab 87:4482-4489
16. Chow CC, Chan WB, Li JKY, Chan NN, Chan MHM, Ko GTC, LO KW, Cockram CS 2003 Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinal Metab 88:581-587
17. Rubin MR, Lee K, Silverberg SJ Raloxifene lowers serum calcium and markers of bone turnover in primary hyperparathyroidism. J Bone Miner Res 17(Suppl 1):SU467
18. Zanchetta JR, Bogado CE 2001 Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 16:189-191
19. Rubin MR, Lee K, McMahon D, Silverberg SJ 2003 Raloxifene lowers serum calcium and markers of bone turnover in primary hyperparathyroidism. J Clin Endocrinol Metab 88:1174-1178
20. Syed ZA, Khan AA 2000 Skeletal effects of primary hyperparathyroidism. Endocr Pract 6:385-388
21. Greenspan S, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan W, Kher U, Gertz B 1996 Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Phys 108:230-238
22. Silverberg SJ, Gartenbarg F, Jacobs TP, Shane E, Siris E, Staron RB, McMahon DJ, Bilezikian JP 1995 Increased bone mineral density after parathyroidectomy in primary hyperparathyioidism. J Clin Endocrinol Metab 80:729-734
23. Utiger RD 1999 Treatment of primary hyperparathyroidism. N Engl J Med 341:1301-1302
24. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J 2001 Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 19:558-567